Cell-penetrating peptides: Application in vaccine delivery

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1805, Issue 1, 2010, Pages 25-34

  Brooks, Nicole A ^a,b   Pouniotis, Dodie S ^b   Tang, Choon Kit ^a   Apostolopoulos, Vasso ^a   Pietersz, Geoffrey A ^a  

^a BURNET INSTITUTE   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

Antigen presentation; Cancer vaccine; Cell penetrating peptide; Penetratin; Vaccine delivery

Indexed keywords

ANTENNAPEDIA SERYLISOLEUCYLISOLEUCYLASPARAGINE; CANCER VACCINE; CELL PENETRATING PEPTIDE; DNA VACCINE; DODECYL SULFATE SODIUM; HYBRID PROTEIN; MAREK DISEASE VACCINE; PEPTIDE VACCINE; PROTEIN VP22; TRANSACTIVATOR CARCINOEMBRYONIC ANTIGEN CPG OLIGODEOXYNUCLEOTIDE FUSION PROTEIN; TRANSACTIVATOR CARCINOEMBRYONIC ANTIGEN FUSION PROTEIN; TRANSACTIVATOR OVALBUMIN FUSION PROTEIN; TRANSACTIVATOR P53 FUSION PROTEIN; TRANSACTIVATOR TYROSINASE RELATED FUSION PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCYTOSIS; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTERNALIZATION; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; VARIABLE NUMBER OF TANDEM REPEAT;

CANCER VACCINES; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 75349097011     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.09.004     Document Type: Review

References (110)

1. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
2. Cashman S.M., Sadowski S.L., Morris D.J., Frederick J., and Kumar-Singh R. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol. Ther. 6 (2002) 813-823
3. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
4. Trehin R., Krauss U., Muff R., Meinecke M., Beck-Sickinger A.G., and Merkle H.P. Cellular internalization of human calcitonin derived peptides in MDCK monolayers: a comparative study with Tat(47-57) and penetratin(43-58). Pharm. Res. 21 (2004) 33-42
5. Elmquist A., Lindgren M., Bartfai T., and Langel U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell. Res. 269 (2001) 237-244
6. Fernandez-Carneado J., Kogan M.J., Castel S., and Giralt E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew. Chem. Int. Ed. Engl. 43 (2004) 1811-1814
7. Johnson J.R., Jiang H., and Smith B.D. Zinc(II)-coordinated oligotyrosine: a new class of cell penetrating peptide. Bioconjug. Chem. 19 (2008) 1033-1039
8. Morris M.C., Vidal P., Chaloin L., Heitz F., and Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 (1997) 2730-2736
9. Pooga M., Hallbrink M., Zorko M., and Langel U. Cell penetration by transportan. FASEB J. 12 (1998) 67-77
10. Oehlke J., Scheller A., Wiesner B., Krause E., Beyermann M., Klauschenz E., Melzig M., and Bienert M. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1414 (1998) 127-139
11. Morris M.C., Depollier J., Mery J., Heitz F., and Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19 (2001) 1173-1176
12. Rojas M., Donahue J.P., Tan Z., and Lin Y.Z. Genetic engineering of proteins with cell membrane permeability. Nat. Biotechnol. 16 (1998) 370-375
13. Crombez L., Aldrian-Herrada G., Konate K., Nguyen Q.N., McMaster G.K., Brasseur R., Heitz F., and Divita G. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther. 17 (2009) 95-103
14. Matsushita M., Tomizawa K., Moriwaki A., Li S.T., Terada H., and Matsui H. A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation. J. Neurosci. 21 (2001) 6000-6007
15. Yang Y., Wang X., and Dai W. Human Sgo1 is an excellent target for induction of apoptosis of transformed cells. Cell Cycle 5 (2006) 896-901
16. Pero S.C., Shukla G.S., Cookson M.M., Flemer Jr. S., and Krag D.N. Combination treatment with Grb7 peptide and doxorubicin or trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br. J. Cancer 96 (2007) 1520-1525
17. Turner J.J., Jones S., Fabani M.M., Ivanova G., Arzumanov A.A., and Gait M.J. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol. Dis. 38 (2007) 1-7
18. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., Barnes P.J., Sproat B.S., Gait M.J., and Lindsay M.A. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 18 (2007) 1450-1459
19. Meade B.R., and Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59 (2007) 134-140
20. Berry C.C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomed 3 (2008) 357-365
21. Shishido T., Yonezawa D., Iwata K., Tanaka T., Ogino C., Fukuda H., and Kondo A. Construction of arginine-rich peptide displaying bionanocapsules. Bioorg. Med. Chem. Lett. 19 (2009) 1473-1476
22. Kale A.A., and Torchilin V.P. "Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J. Liposome Res. 17 (2007) 197-203
23. Pappalardo J.S., Quattrocchi V., Langellotti C., Di Giacomo S., Gnazzo V., Olivera V., Calamante G., Zamorano P.I., Levchenko T.S., and Torchilin V.P. Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J. Control Release 134 (2009) 41-46
24. Wei B., Wei Y., Zhang K., Wang J., Xu R., Zhan S., Lin G., Wang W., Liu M., Wang L., Zhang R., and Li J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide. Biomed. Pharmacother. 63 (2008) 313-318
25. Gao C., Mao S., Ditzel H.J., Farnaes L., Wirsching P., Lerner R.A., and Janda K.D. A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorg. Med. Chem. 10 (2002) 4057-4065
26. Banoczi Z., Tantos A., Farkas A., Tompa P., Friedrich P., and Hudecz F. Synthesis of cell-penetrating conjugates of calpain activator peptides. Bioconjug. Chem. 18 (2007) 130-137
27. Fischer R., Waizenegger T., Kohler K., and Brock R. A quantitative validation of fluorophore-labelled cell-permeable peptide conjugates: fluorophore and cargo dependence of import. Biochim. Biophys. Acta 1564 (2002) 365-374
28. Chen B., Liu Q., Zhang Y., Xu L., and Fang X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 24 (2008) 11866-11871
29. Lagerholm B.C. Peptide-mediated intracellular delivery of quantum dots. Methods Mol. Biol. 374 (2007) 105-112
30. Mittendorf E.A., Peoples G.E., and Singletary S.E. Breast cancer vaccines: promise for the future or pipe dream?. Cancer 110 (2007) 1677-1686
31. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23 (2005) 975-1028
32. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57 (2005) 579-596
33. Foerg C., and Merkle H.P. On the biomedical promise of cell penetrating peptides: limits versus prospects. J. Pharm. Sci. 97 (2008) 144-162
34. Yang Z., Wang L., Wang H., Shang X., Niu W., Li J., and Wu Y. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol. Immunol. 45 (2008) 1674-1681
35. Wang H.Y., Fu T., Wang G., Zeng G., Perry-Lalley D.M., Yang J.C., Restifo N.P., Hwu P., and Wang R.-F. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J. Clin. Invest. 109 (2002) 1463-1470
36. Lundberg P., and Langel U. A brief introduction to cell-penetrating peptides. J. Mol. Recogn. JMR 16 (2003) 227-233
37. Prochiantz A. Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr. Opin. Neurobiol. 6 (1996) 629-634
38. Pooga M., Kut C., Kihlmark M., Hallbrink M., Fernaeus S., Raid R., Land T., Hallberg E., Bartfai T., and Langel U. Cellular translocation of proteins by transportan. FASEB J. Official Publication Of The Federation Of American Societies For Experimental Biology 15 (2001) 1451-1453
39. Wagstaff K.M., and Jans D.A. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 13 (2006) 1371-1387
40. Joliot A., and Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell. Biol. 6 (2004) 189-196
41. Magzoub M., and Gräslund A. Cell-penetrating peptides: [corrected] from inception to application. Q. Rev. Biophys. 37 (2004) 147-195
42. Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
43. Schutze-Redelmeier M.P., Gournier H., Garcia-Pons F., Moussa M., Joliot A.H., Volovitch M., Prochiantz A., and Lemonnier F.A. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J. Immunol. (Baltimore, Md: 1950) 157 (1996) 650-655
44. Weidt G., Utermohlen O., Zerrahn J., Reimann J., Deppert W., and Lehmann-Grube F. CD8+ T lymphocyte-mediated antiviral immunity in mice as a result of injection of recombinant viral proteins. J. Immunol. (Baltimore, Md: 1950) 153 (1994) 2554-2561
45. Chikh G., Bally M., and Schutze-Redelmeier M.P. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J. Immunol. Methods 254 (2001) 119-135
46. White W.I., Cassatt D.R., Madsen J., Burke S.J., Woods R.M., Wassef N.M., Alving C.R., and Koenig S. Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine 13 (1995) 1111-1122
47. Fischer P.M. Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006. Med. Res. Rev. 27 (2007) 755-795
48. Lu J., Wettstein P.J., Higashimoto Y., Appella E., and Celis E. TAP-independent presentation of CTL epitopes by Trojan antigens. J. Immunol. (Baltimore, Md: 1950) 166 (2001) 7063-7071
49. Shibagaki N., and Udey M.C. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol. (Baltimore, Md: 1950) 168 (2002) 2393-2401
50. Shibagaki N., and Udey M.C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur. J. Immunol. 33 (2003) 850-860
51. Justesen S., Buus S., Claesson M.H., and Pedersen A.E. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Immunology 122 (2007) 326-334
52. Woo S.-J., Kim C.-H., Park M.-Y., Kim H.-S., Sohn H.-J., Park J.-S., Kim H.-J., Oh S.-T., and Kim T.-G. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci. 99 (2008) 1034-1039
53. Pietersz G.A., Li W., Apostolopoulos V., and 16-mer peptide A. (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the class I pathway. Vaccine 19 (2001) 1397-1405
54. Pouniotis D.S., Apostolopoulos V., and Pietersz G.A. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology 117 (2006) 329-339
55. Apostolopoulos V., Pouniotis D.S., van Maanen P.J., Andriessen R.W., Lodding J., Xing P.-X., McKenzie I.F.C., Loveland B.E., and Pietersz G.A. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine 24 (2006) 3191-3202
56. Wu A., Oh S., Gharagozlou S., Vedi R.N., Ericson K., Low W.C., Chen W., and Ohlfest J.R. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J. Immunother. (Hagerstown, Md: 1997) 30 (2007) 789-797
57. Schutze-Redelmeier M.-P.M., Kong S., Bally M.B., and Dutz J.P. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22 (2004) 1985-1991
58. Pietersz G.A., Pouniotis D.S., and Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr. Med. Chem. 13 (2006) 1591-1607
59. Dakappagari N.K., Sundaram R., Rawale S., Liner A., Galloway D.R., and Kaumaya P.T.P. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J. Pept. Res.: Official Journal Of The American Peptide Society 65 (2005) 189-199
60. Gupta B., Levchenko T.S., and Torchilin V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug. Deliv. Rev. 57 (2005) 637-651
61. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., Engleman E.G., and Rothbard J.B. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. (Baltimore, Md: 1950) 159 (1997) 1666-1668
62. Pietersz G.A., Li W., Osinski C., Apostolopoulos V., and McKenzie I.F. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 18 (2000) 2059-2071
63. Hung C.F., Cheng W.F., Chai C.Y., Hsu K.F., He L., Ling M., and Wu T.C. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J. Immunol. 166 (2001) 5733-5740
64. Peng S., Trimble C., Ji H., He L., Tsai Y.C., Macaes B., Hung C.F., and Wu T.C. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J. Biomed. Sci. 12 (2005) 689-700
65. Kim T.W., Hung C.F., Kim J.W., Juang J., Chen P.J., He L., Boyd D.A., and Wu T.C. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther. 15 (2004) 167-177
66. Normand N., van Leeuwen H., and O'Hare P. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276 (2001) 15042-15050
67. Elliott G., and O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 6 (1999) 149-151
68. + T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. J. Leukoc. Biol. 78 (2005) 401-411
69. Saha S., Yoshida S., Ohba K., Matsui K., Matsuda T., Takeshita F., Umeda K., Tamura Y., Okuda K., Klinman D., and Xin K.Q. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 354 (2006) 48-57
70. Zheng C.F., Brownlie R., Huang D.Y., Babiuk L.A., and van Drunen Littel-van den Hurk S. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch. Virol. 151 (2006) 985-993
71. Zheng C., Babiuk L.A., and van Drunen Littel-van den Hurk S. Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. J. Virol. 79 (2005) 1948-1953
72. Zhao W., Xiao S.B., Fang L.R., Jiang Y.B., Song Y.F., Yan L., Yu X.L., and Chen H.C. [Immunogenicity of DNA vaccine expressing GP5 of porcine reproductive and respiratory syndrome virus fused with VP22 of bovine herpesvirus 1]. Sheng Wu Gong Cheng Xue Bao 21 (2005) 725-730
73. Hung C.F., He L., Juang J., Lin T.J., Ling M., Wu T.C., and Improving D. vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J. Virol. 76 (2002) 2676-2682
74. Oliveira S.C., Harms J.S., Afonso R.R., and Splitter G.A. A genetic immunization adjuvant system based on BVP22-antigen fusion. Hum. Gene Ther. 12 (2001) 1353-1359
75. Astriab-Fisher A., Sergueev D.S., Fisher M., Shaw B.R., and Juliano R.L. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60 (2000) 83-90
76. Niidome T., Ohmori N., Ichinose A., Wada A., Mihara H., Hirayama T., and Aoyagi H. Binding of cationic alpha-helical peptides to plasmid DNA and their gene transfer abilities into cells. J. Biol. Chem. 272 (1997) 15307-15312
77. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., and Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271 (1996) 18188-18193
78. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., and Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003) 585-590
79. Ross M.F., Filipovska A., Smith R.A., Gait M.J., and Murphy M.P. Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem. J. 383 (2004) 457-468
80. Thoren P.E., Persson D., Isakson P., Goksor M., Onfelt A., and Norden B. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem. Biophys. Res. Commun. 307 (2003) 100-107
81. Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., and Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8 (2007) 848-866
82. Jones S.W., Christison R., Bundell K., Voyce C.J., Brockbank S.M., Newham P., and Lindsay M.A. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br. J. Pharmacol. 145 (2005) 1093-1102
83. Richard J.P., Melikov K., Brooks H., Prevot P., Lebleu B., and Chernomordik L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 280 (2005) 15300-15306
84. Saalik P., Elmquist A., Hansen M., Padari K., Saar K., Viht K., Langel U., and Pooga M. Protein cargo delivery properties of cell-penetrating peptides. A comparative study. Bioconjug. Chem. 15 (2004) 1246-1253
85. Kaplan I.M., Wadia J.S., and Dowdy S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release 102 (2005) 247-253
86. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
87. Binder H., and Lindblom G. Charge-dependent translocation of the Trojan peptide penetratin across lipid membranes. Biophys. J. 85 (2003) 982-995
88. Hallbrink M., Oehlke J., Papsdorf G., and Bienert M. Uptake of cell-penetrating peptides is dependent on peptide-to-cell ratio rather than on peptide concentration. Biochim. Biophys. Acta 1667 (2004) 222-228
89. Marty C., Meylan C., Schott H., Ballmer-Hofer K., and Schwendener R.A. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell. Mol. Life Sci. 61 (2004) 1785-1794
90. Tseng Y.L., Liu J.J., and Hong R.L. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol. Pharmacol. 62 (2002) 864-872
91. Khalil I.A., Kogure K., Futaki S., and Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 281 (2006) 3544-3551
92. El-Andaloussi S., Jarver P., Johansson H.J., and Langel U. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem. J. 407 (2007) 285-292
93. Tunnemann G., Martin R.M., Haupt S., Patsch C., Edenhofer F., and Cardoso M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 20 (2006) 1775-1784
94. Vandenbroucke R.E., De Smedt S.C., Demeester J., and Sanders N.N. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim. Biophys. Acta 1768 (2007) 571-579
95. Nativo P., Prior I.A., and Brust M. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano 2 (2008) 1639-1644
96. Manceur A., Wu A., and Audet J. Flow cytometric screening of cell-penetrating peptides for their uptake into embryonic and adult stem cells. Anal. Biochem. 364 (2007) 51-59
97. Al-Taei S., Penning N.A., Simpson J.C., Futaki S., Takeuchi T., Nakase I., and Jones A.T. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug. Chem. 17 (2006) 90-100
98. Fischer R., Kohler K., Fotin-Mleczek M., and Brock R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279 (2004) 12625-12635
99. Sugita T., Yoshikawa T., Mukai Y., Yamanada N., Imai S., Nagano K., Yoshida Y., Shibata H., Yoshioka Y., Nakagawa S., Kamada H., Tsunoda S.I., and Tsutsumi Y. Comparative study on transduction and toxicity of protein transduction domains. Br. J. Pharmacol. 153 (2008) 1143-1152
100. Ghibaudi E., Boscolo B., Inserra G., Laurenti E., Traversa S., Barbero L., and Ferrari R.P. The interaction of the cell-penetrating peptide penetratin with heparin, heparansulfates and phospholipid vesicles investigated by ESR spectroscopy. J. Pept. Sci. 11 (2005) 401-409
101. Abes S., Moulton H., Turner J., Clair P., Richard J.P., Iversen P., Gait M.J., and Lebleu B. Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans. 35 (2007) 53-55
102. Silhol M., Tyagi M., Giacca M., Lebleu B., and Vives E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur. J. Biochem. 269 (2002) 494-501
103. Tyagi M., Rusnati M., Presta M., and Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001) 3254-3261
104. Nakase I., Niwa M., Takeuchi T., Sonomura K., Kawabata N., Koike Y., Takehashi M., Tanaka S., Ueda K., Simpson J.C., Jones A.T., Sugiura Y., and Futaki S. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10 (2004) 1011-1022
105. Caminschi I., Lahoud M.H., and Shortman K. Enhancing immune responses by targeting antigen to DC. Eur. J. Immunol. 39 (2009) 931-938
106. Tanaka Y., Dowdy S.F., Linehan D.C., Eberlein T.J., and Goedegebuure P.S. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J. Immunol. 170 (2003) 1291-1298
107. Viehl C.T., Becker-Hapak M., Lewis J.S., Tanaka Y., Liyanage U.K., Linehan D.C., Eberlein T.J., and Goedegebuure P.S. A tat fusion protein-based tumor vaccine for breast cancer. Ann. Surg. Oncol. 12 (2005) 517-525
108. Batchu R.B., Moreno A.M., Szmania S.M., Bennett G., Spagnoli G.C., Ponnazhagan S., Barlogie B., Tricot G., and van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 65 (2005) 10041-10049
109. Scheller N., Furtwangler R., Sester U., Maier R., Breinig T., and Meyerhans A. Human cytomegalovirus protein pp65: an efficient protein carrier system into human dendritic cells. Gene Ther. 15 (2008) 318-325
110. Viehl C.T., Tanaka Y., Chen T., Frey D.M., Tran A., Fleming T.P., Eberlein T.J., and Goedegebuure P.S. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res. Treat. 91 (2005) 271-278